2024 Opinion

What is required for better progress in clinical and scientific andrology involving sperm assessments?
Lars Björndahl
Asian J Androl : 229-232; 10.4103/aja202380
Full Text | PDF [152]

Prostate cancer biology from clinical prognostic low- to intermediate-risk groups: looking up at the multiple patterns tracking the way forward
Antonio Benito Porcaro
Asian J Androl : 557-558; 10.4103/aja20246
Full Text | PDF [104]

Prostate cancer: screening and early detection
Orazio Caffo, Antonello Veccia
Asian J Androl : 559-561; 10.4103/aja202417
Full Text | PDF [104]

PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice
Ricevuto, Enrico1,2; Morgani, Celeste1; Seri, Fabrizia1; Bruera, Gemma1
Asian J Androl : 567-568; 10.4103/aja202468
Full Text | PDF [141]

Active surveillance in low- and intermediate-risk prostate cancer
Cerbone, Linda1; Regine, Giovanni2; Calabrò, Fabio3
Asian J Androl : 582-583; 10.4103/aja202423
Full Text | PDF [160]

PSMA PET/CT in the low- to intermediate-risk prostate cancer: when and why?
Luca Sofia1, Matteo Bauckneht1,2
Asian J Androl : 584-586; 10.4103/aja20244
Full Text | PDF [103]